Efficacy of Muscle Exercise in Patients with Muscular Dystrophy: A Systematic Review Showing a Missed Opportunity to Improve Outcomes by S. Gianola et al.
Efficacy of Muscle Exercise in Patients with Muscular
Dystrophy: A Systematic Review Showing a Missed
Opportunity to Improve Outcomes
Silvia Gianola1*, Valentina Pecoraro , Simone Lambiase , Roberto Gatti   , Giuseppe Banfi1 2 4,5
Lorenzo Moja1,5
1Clinical Epidemiology Unit, IRCCS Orthopedic Institute Galeazzi, Milan, Italy, 2
Analysis, Vita-Salute San Raffaele University, Milan, Italy, 4 IRCCS Orthopedic Institute Galeazzi, Milan, Italy, 5Department of Biomedical Sciences for Health, University
of Milan, Milan, Italy
Abstract
Background: Although muscular dystrophy causes muscle weakness and muscle loss, the role of exercise in the
management of this disease remains controversial.
Objective: The purpose of this systematic review is to evaluate the role of exercise interventions on muscle strength in
patients with muscular dystrophy.
Methods: We performed systematic electronic searches in Medline, Embase, Web of Science, Scopus and Pedro as well as a
list of reference literature. We included trials assessing muscle exercise in patients with muscular dystrophy. Two reviewers
independently abstracted data and appraised risk of bias.
Results: We identified five small (two controlled and three randomized clinical) trials comprising 242 patients and two
ongoing randomized controlled trials. We were able to perform two meta-analyses. We found an absence of evidence for a
difference in muscle strength (MD 4.18, 95% CIs - 2.03 to 10.39; p = 0.91) and in endurance (MD20.53, 95% CIs –1.11 to 0.05;
p = 0.26). In both, the direction of effects favored muscle exercise.
Conclusions: The first included trial about the efficacy of muscular exercise was published in 1978. Even though some
benefits of muscle exercise were consistently reported across studies, the benefits might be due to the small size of studies
and other biases. Detrimental effects are still possible. After several decades of research, doctors cannot give advice and
patients are, thus, denied basic information. A multi-center randomized trial investigating the strength of muscles, fatigue,
and functional limitations is needed.
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Background
Muscular dystrophy is a genetic disorder that gradually weakens
the body’s muscles [1] limiting person’s functional capacity [2]. It’s
caused by incorrect or missing genetic information that prevents
the body from making the proteins needed to build and maintain
healthy muscles [1].
During the last three decades, important progress has been
made in the field of muscular dystrophies, leading to the discovery
of molecular [3], and genetic [4] causes underlying the disease [5].
There is no cure for muscular dystrophy: scientific advances have
not been paralleled by discoveries of effective therapeutic tools so
far. Patients have to rely on symptomatic treatments in which
continuous physiotherapy is supposed to play a central role [6].
It has been debated for many years whether muscle exercise is
beneficial or harmful for patients with myopathic disorders. The
role of exercise in the management of these patients remains
controversial [6,7]. Because muscle weakness is the main problem,
muscular exercise would be valuable if it helped to counteract the
loss of muscle tissue and strength [6]. This theoretical model is
established in healthy individuals [8,9] and in patients with many
neurological diseases (e.g. stroke [10,11], multiple sclerosis [12],
etc.). However, hand weakness caused by overwork has been
suggested in case reports of patients with facioscapulohumeral
muscular dystrophy [13] and scapuloperoneal muscular dystrophy
[14], and has also been suggested from animal studies [15,16].
Given that the evidence for a deleterious effect of strength exercise
in patients with muscular dystrophy is largely anecdotal, it is
important to conduct a systematic search to point out the effects of
muscular exercise in experimental settings.
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Objective
The purpose of this systematic review is to evaluate the role of
exercise interventions on muscle strength in patients with muscular
dystrophy.
Methods
Eligibility Criteria
Trials were included if they met the following criteria: 1)
randomized or quasi-randomized controlled trials (RCTs) (name-
ly, controlled trials with inappropriate randomization strategies
[17]); 2) inclusion of patients with Duchenne’s muscular dystrophy
(DMD), Becker’s muscular dystrophy (BMD), limb-girdle dystro-
phy (LD), facioscapulohumeral dystrophy (FSHD) and myotonic
dystrophy (MyD); 3) muscular exercise was the core of the
intervention and was assessed on the basis of muscle strengthening
or physical capacity and expressed as a peak torque of strength,
motor function or fatigue; and 4) training lasted at least ten weeks.
Eligibility was not restricted by language, type of publication, or
patients’ age. Trials were irrespective of the type of control, with
the caveat to exclude any type of exercise. We included the
following categories: no intervention at all, usual care without
exercise, and controlateral limb controls (i.e. the parts of the body
were randomized to the intervention or control groups). Our
approach was ‘inclusive’ so as to obtain a pragmatic overall picture
of research in this field.
Search Strategy
To identify the studies, we searched the following electronic
databases: Medline (since 1966), Embase (since 1974), Web of
Science (since 1950), Scopus (since 1996) and Pedro (since 1999).
The adopted search strategy, which was developed using as key
words ‘muscular dystrophy’, ‘physical therapy’, ‘rehabilitation,’
was similar across all databases. We examined the reference list of
potentially eligible studies and contacted experts in the field to
identify additional trials. The last search was run in June 2012 and
it was up to date in February 2013.
Outcomes
The primary outcome was the peak torque of muscle strength.
Secondary outcomes were motor abilities, endurance, and the
adverse effect fatigue.
Study Selection
The literature search was conducted by one investigator (SG).
Two researchers (SG and VP) independently screened all studies
for eligibility by titles and abstracts. Full texts were then evaluated
for inclusion. Disagreements between reviewers were resolved by
consensus; if no agreement could be reached, the opinion of a
third author (LM) was consulted to be determinant.
Data Collection
Two authors (SG and VP) independently extracted and entered
the data from studies into the data extraction form. Information
was extracted from each included trial regarding: (i) characteristics
of trial participants (age, sex, type of dystrophy and muscle
involved); (ii) characteristics of studies (study design, study year and
country where the study was performed); (iii) outcomes (peak
torque of muscle strength, motor abilities, endurance and fatigue).
Disagreements were resolved by discussion; if no accord was
reached, it was planned that a third author (LM) would decide the
matter. Authors were contacted if the reported data were
insufficient or unclear.
Quality Assessment
Two reviewers (SG, VP) independently evaluated the risk of bias
in the following domains: study design, randomization, blinding of
outcome assessors, reporting of inclusion and exclusion criteria,
withdrawals and dropouts, and adverse events. Every domain
could be classified as ‘‘high’’ or ‘‘low’’ risk of bias. If the
information reported in the paper was not sufficient, the domain
was defined as ‘‘unclear’’. Two reviewers (SG and VP) indepen-
dently assessed the risk of bias. A third reviewer (LM) was
consulted in instances where consensus could not be reached
between the two reviewers.
Statistics
To explore effect modifiers, we pooled studies trough a
subgroup analysis according to the type of dystrophy, strengthen-
ing exercise, control, and muscle involved. All data were
continuous. To quantify the effect associated with each outcome,
we used the mean difference (MD) or standardized mean
difference (SMD) with a 95% confidence interval (CI) according
to the scales measuring the outcome. We assumed that clinical
heterogeneity was pervasive in this field, given the potential wide
range of patient populations, the types of intervention (e.g.
different for intensity or duration), and the types of controls. We
summarized data in a meta-analysis using the random effect
models described by DerSimonian and Laird [18] according to the
inverse variance method. We assessed the presence of heteroge-
neity utilizing the I-squared statistic (I2), which estimates the
percentage of variation between study results that is due to
heterogeneity rather than sampling error. The I2 statistic indicated
the percentage of variability due to between-study (or inter-study)
variability as opposed to within-study (or intra-study) variability
[19]. An I2 value greater than 50% was classified as substantially
heterogeneous. For the meta-analyses, we used the longest
available follow-up data. If no follow-up data were available we
used end-of treatment data.
All analyses were done with Review Manager (RevMan5)
software version 5.2.
Results
Studies Selection
The literature search identified 4283 references. After the
exclusion of duplicates and irrelevant references, 58 were left.
Thirty-one were eligible for inclusion, their full texts scrutinized
for further detail. Twenty-four studies were excluded because: i)
they included patients with muscular dystrophy in a wider group
of patients with neuromuscular diseases (n = 6) (7–12); ii) used
interventions combined with other than exercise interventions (e.g.
medication) (n = 3) [20,21,22], had no control group (n = 5)
[23,24,25,26,27], had a healthy control group (n = 7)
[28,29,30,31,32,33] or other interventions as control group
(n = 1) [34]. Results from two trials were reported in more than
one publications [7,35]. We counted these as one entry for meta-
analyses. Finally, seven trials were included
[36,37,38,39,40,41,42], Figure 1.
Study Characteristics
The included studies are three RCTs [38,39,40], two controlled
clinical trials [41,42] and two ongoing RCTs [36,37]. Main
features of the seven trials are summarized in Table 1. Overall,
242 participants were considered, with the number of participants
ranging from 4 to 75. The majority of patients (52%) had FSHD,
followed by MyD (32%) and DMD (16%). In adult dystrophies,
the age of participants ranged from 22 to 48 years. In DMD, the
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Figure 1. Literature flowchart.
doi:10.1371/journal.pone.0065414.g001
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age of participants ranged from 4 to 11 years. All trials were
conducted in Western countries between 1978 and 2011.
Exercises as an intervention proposed by the authors varied by
the following categories: standard strengthening of muscles
[38,39,41,42], a comprehensive group of exercises (e.g. aerobic,
strengthening, flexibility, balance) supported by music [40],
aerobic exercise training (AET) [37], and legs and arms cycling
[36]. For the control, five studies used the patient as a unit of
allocation as two, the anatomical district (i.e. controlateral limb).
All randomized the controls to no training or usual care. The
length period of exercise intervention ranged from 12 weeks to 52
weeks. The outcome measures used to assess muscle strength,
motor function, fatigue and endure are summarized in Table 1.
Methodological Quality
Risk of bias evaluation is reported in Figure 2. Most of the
studies were judged as having a low risk of bias (reported in green).
Three of the five studies were randomized and used a blinded
procedure [38,39,40]. Two of the five studies declared the use of
the random sequence generation [38,40]. All studies reported
details of dropouts or withdrawals. Four of the five reported the
inclusion and exclusion criteria and reported adverse events
[38,39,40,41].
Quantitative Data Synthesis: Effect of Interventions
Muscle strength. Four of the five trials [38,39,41,42]
comprising 102 patients measured the maximal voluntary
isometric contraction (MVIC) with an isokinetic dynamometer.
Three studies [39,41,42] evaluated the knee extensor, one [39]
Figure 2. Risk of bias table. Legend: Red (-) = high risk of bias; Yellow (?) = unknown risk of bias; Green (+) = low risk of bias.
doi:10.1371/journal.pone.0065414.g002
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considered the knee flexor, and one [38] looked at the effect of
training on elbow and ankle flexors.
To underline the cumulative trend effect of exercise, we plotted
graphically (i.e. no meta-analysis) all effects sizes irrespective of
muscle district and dystrophy. In all studies the direction of the
effect of muscular exercise is toward a positive but not significant
change on muscle strength (Figure 3). We meta-analyzed studies to
account for muscle district and dystrophy. Knee extensors were
evaluated in DMD [42] and MyD [39,41]. The effect of muscular
exercise was not significantly different (respectively, MD 0.40 CI
95% 20.15 to 0,95; p = 0.15 and MD 4.18 CI 95% 22.03 to
10.39; p = 0.19) (Figure 4).
Motor abilities. Two studies [39,40], totaling 63 patients,
tested motor abilities using different instruments. Again, both
studies were first plotted without pooling data irrespective of
activities. Across all activities, there was an absence of evidence of
a significant effect of muscular exercise on muscle strength
(Figure 5). When we meta-analyzed results, any combination of
activities resulted in non-significance differences (results not
shown).
Endurance. Two studies [39,40] considered endurance in 63
patients. The results slightly favored exercise in improving the
endurance but the differences were not significant (SMD 20.53;
CI 95% from 21.11 to 0.05; p = 0.26) (Figure 6).
Adverse effect – fatigue. Two studies provided information
about fatigue [38,40]. The results were heterogeneous, preventing
us from meta-analyzing them. Van der Kooi [38] reported that
patients did not experience fatigue or muscle soreness. In
Kierkegaard [40], the post-walk Borg rating of perceived exertion
showed no significant between-group differences after the inter-
vention.
Ongoing Trials
Jansen et al. are studying the effects of low-intensity physical
training on muscle endurance and functional abilities in boys with
DMD [36]. In a three-arms trial, Voet et al. are exploring the
effect of aerobic exercise training (AET) and cognitive-behavioral
therapy (CBT) on the reduction of chronic fatigue in patients with
FSHD [37].
Discussion
Muscular exercise for patients with muscular dystrophy may be
useful, not useful, or detrimental. Our analysis does not exclude
any of these possibilities: the confidence intervals are so wide that
Figure 3. Overall effect of muscular exercise on strength as MVIC.
doi:10.1371/journal.pone.0065414.g003
Figure 4. Effect of muscular exercise on strength as MVIC knee extension.
doi:10.1371/journal.pone.0065414.g004
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they cover all the possibilities, from ample benefit to possible
disadvantage. This might depend on the wide clinical heteroge-
neity between experimental design and clinical characteristics in
the studies, or on the small numbers of patients accumulated in
more than 30 years of research [6]. The implication for practice is
that exercise can neither be recommended nor excluded from
therapies, given their unknown benefit. In a disease still without a
cure, the research community was unable to provide any answer of
interest to the basic question posed by all patients and their
relatives:‘‘Is muscle exercise beneficial or detrimental in patients with
muscular dystrophies?’’.
Only five published and two ongoing trials were retrieved from
our extensive search. Although considered as rare diseases,
dystrophies do not have a negligible prevalence. Considering the
most frequent dystrophy, MyD, there is a conservative prevalence
of at least 1 in 8000 people worldwide [43] and a prevalence rate
of 2.2–5.5 per 100 000 inhabitants in Western Europe [44]. This is
only focusing on one type of dystrophy. A crude estimate of the
number of patients diagnosed with muscular dystrophy, who could
have been randomized to answer to our question, can be made
from this rate. From 1978, when patients were enrolled in the first
RCT, until today, 36 900 new patients were diagnosed with MyD
in Europe alone. Only 0.6% were randomized each year, one
patient for every 174. If we consider patients in USA, Australasia,
and the rest of Europe, estimating 1% as the feasible proportion of
patients eligible for RCTs, at least 8 750 additional patients would
have led to a clearer – and earlier - recognition of the benefits or
risks of exercise, thereby potentially shifting the advice given to
patients based on theories as well as anecdotic experience and
evidence.
Patients with dystrophies are cared for and monitored in few
centers. All centers can be easily connected in a network. In this
perspective, a multicentre clinical trial is essential. A research
infrastructure supporting the trial, such as European Clinical
Research Infrastructure Network (ECRIN), might additionally be
of great value [45]. Results stratified by age, sex, type and duration
of disease, and symptom severity could well be an attainable goal.
The pioneering studies with active programs of exercises in
dystrophy were done by Abrahamson and Rogoff [24] and by
Hoberman [23] in the 1950 s. Their findings on exercise to
strengthen muscles in dystrophy, however, are hard to interpret
since they did not use un-exercised control patients with
comparable disease severity [46]. Controls are important in any
trial but essential in muscular dystrophy that often involves very
young patients. In this case, three progressing phenomena have to
be controlled: 1) physiological muscle volume increase, 2)
Figure 5. Overall effect of muscular exercise on motor function.
doi:10.1371/journal.pone.0065414.g005
Figure 6. Effect of muscular exercise on endurance.
doi:10.1371/journal.pone.0065414.g006
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musculoskeletal growth that produce a load increase, hindering the
functional abilities if not accompanied by a contemporary increase
of muscle strength and, 3) the degenerative process of muscular
dystrophy itself [42]. Major shortcomings of studies about exercise
in muscular dystrophy include the lack of appropriate control
groups and small sample sizes, often fewer than 35 patients
[36,38,39,40,41,42]. Finally, we noted scant and variable use of
outcome measures such as fatigue and motor abilities.
Studies in this field are not easy and face a number of practical
difficulties. First, because of large inter-individual differences,
training programs must be adapted to each patient’s physical
ability and capacity (28, 34). Clinical care of these patients is
complex since they can present multiple severe conditions. This
status might be a barrier against their inclusion in standardized
experiments [47] and can worry health professionals about
potential worsening clinical conditions. Second, non-adherence
to an exercise plan is an ever-present threat to the validity and
outcome of any intervention study, especially those in which
people with muscular dystrophy are involved as cognitive and
behavioral problems are associated aspects of the disorder (34). In
addition, progressive loss of muscle function is complicated by
cardio-respiratory co-morbidity, progressive joint contractures,
and deformity. Despite the difficulties of conducting RCTs in this
field, the two ongoing RCTs involving 30 DMD patients and 75
FSHD patients [36,37] are welcome. Although the total sample
size is limited, these RCT are of great value and will add to our
scarce knowledge.
Patients and clinicians need to make well-informed decisions.
The strident mismatch between patient priorities and research
agenda has been vibrantly criticized [48]. Several reasons have
been proposed as to why research is still so remote from patients’
needs. The research system gives priority to questions that may
have limited clinical impact, moving through hypotheses without
always completing earlier studies, and assigning low – or no –
priority to the publication of negative results. Advocacy groups for
muscular dystrophy invest millions to support research, hoping to
promote better care [48]. Although they have the responsibility for
allocating funding, hypotheses are often driven by research
professionals- competing interests, academic and financial, may,
therefore, be involved [49]. Liberati (34) proposed that the
essential components of any new research governance strategy are:
1) analysis of existing and ongoing research, 2) including patients
when setting the research agenda, 3) reducing the role of experts
and stakeholders with vested interests, not only financial. The most
innovative aspect of the Liberati’s thinking was the call for a
formal and substantial commitment by all stakeholders (charities,
government, drug companies) to gather and discuss the research
agenda. Each funding entity, driven by its selection of priorities
from its limited point of view, would, thus, be obliged to place its
priorities into a wider perspective, making their choices more
transparent and efficient. This intellectual inheritance has become
the fulcrum of an international movement - referred as the
Liberati initiative - to help those who fund health research to be
fully aware of what matters concerning patients, physicians,
institutions, and all the other members of society who are involved
[50]. The aim is to integrate the experiences and preferences of
patients with the pipeline of scientific research so as to promote the
acknowledgement of uncertainty about the effect of treatment
[51,52].
This review has some limitations. We included studies with
controlateral limb exercise although there are reports that
unilateral training enhances strength and performance in the
controlateral untested limb [53]. Neural adaptations are possibly
responsible for controlateral strength gains [54,55]. Discarding
these studies would have further reduced the information we
collected. If there was any bias, the inclusion of these studies would
have diluted the effect. It would have been ideal to analyze the
findings with and without these studies in a sensitivity analysis.
However, given the paucity of patients, we missed this opportu-
nity. Finally, a Cochrane review limited to controlateral limb
exercise studies came to similar inconclusive conclusions [56].
Conclusions
Our meta-analysis is inconclusive. Only five RCTs addressed
the question of whether muscular exercise improves muscle
strength in a dystrophic population compared to no intervention.
Exercise might be useful, not useful, or even detrimental. Although
it is accepted that exercise has a positive role in many diseases, we
cannot generalize this finding to muscular dystrophy. Even though
the effects were consistent across studies, the benefit was limited in
size and might have been due to small-study effect or other biases.
Detrimental effects also remain a possibility. Practice recommen-
dations regarding the prescription of exercise should stress the
uncertainty surrounding the utility of muscle exercise. Patients
today must decide whether to start or continue exercise on the
basis of expert opinions or anecdotic experience at best. There is
simply no evidence about the type, frequency, and intensity of
exercise. RCTs targeting this question are urgently needed. A new
research governance strategy for neuromuscular disorders should
be adopted, beginning by concentrating efforts and optimizing
funding research through few multi-center trials that will answer
questions that matter to patients. The strength of muscles, fatigue
and functional limitations, as well as pain need to be considered in
the next generation of RCTs.
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